StockData
Kairos Pharma, LTD. logo

Kairos Pharma, LTD. (KAPA) stock

KAPANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$0.40−0.01 (-1.70%)

Close on Nov 17, 2026Market cap $1.49MP/E –Yield –

Kairos Pharma enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Kairos Pharma's enterprise value was $8.30M on Nov 11, 2026, against $115.93M a year earlier. Over the last 2 years it ranged from $8.30M to $164.64M, with a median of $88.75M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$8.30M-91.5%
2025Dec 31, 2025$97.91M-26.6%
2024Dec 31, 2024$133.47M–

More Kairos Pharma figures

See a number that looks wrong?